Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin

T. Kadar, T. W. Redding, M. Ben-David, Andrew V Schally

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Membrane receptors for luteinizing hormone-releasing hormone (LH-RH), somatostatin, and prolactin (PRL) were investigated in the Dunning R-3327H rat prostate adenocarcinoma specimens after in vivo treatment with microcapsules of the agonist [D-Trp6]LH-RH and the somatostatin analog RC-160. The LH-RH receptors showed a low-binding affinity (K(d) = 54 nM) and high capacity (B(max) = 12.0 pmol/mg). Treatment with the [D-Trp6]LH-RH decreased the binding affinity (K(d) = 0.52 μM). Specific somatostatin receptors, with K(d) = 1.3 nM and B(max) = 543 pmol/mg, were also found. Treatment with [D-Trp6]LH-RH lowered B(max) to 44 fmol/mg, and administration of RC-160 reduced K(d) to 30 nM. After the combined treatment with the two analogs, K(d) and B(max) were decreased. Specific PRL receptors (K(d) = 0.72 nM; B(max) = 161 fmol/mg) were also detected. Treatment with either analog reduced B(max) by 50%, but a much greater reduction of PRL binding capacity was revealed after in vitro dissociation of the bound endogenous PRL by MgCl2. The dramatic fall in the total number of PRL receptors after combination treatment with both analogs could be partially responsible for the decrease in the weight and volume of prostate tumors. The findings support the concept that analogs of LH-RH and somatostatin can inhibit tumors directly through their own respective receptors. One of several mechanisms of the antineoplastic activity of these analogs could be the elimination of tumor growth-promoting effect of PRL by the reduction of the total number of PRL receptors.

Original languageEnglish
Pages (from-to)890-894
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume85
Issue number3
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Prolactin Receptors
Somatostatin Receptors
Somatostatin
Gonadotropin-Releasing Hormone
Prolactin
Prostatic Neoplasms
LHRH Receptors
Prostate
Magnesium Chloride
Tumor Burden
Antineoplastic Agents
Capsules
Neoplasms
Adenocarcinoma
Weights and Measures
Membranes
Growth
vapreotide

ASJC Scopus subject areas

  • General
  • Genetics

Cite this

@article{152175a6a06f4424929809b67121242f,
title = "Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin",
abstract = "Membrane receptors for luteinizing hormone-releasing hormone (LH-RH), somatostatin, and prolactin (PRL) were investigated in the Dunning R-3327H rat prostate adenocarcinoma specimens after in vivo treatment with microcapsules of the agonist [D-Trp6]LH-RH and the somatostatin analog RC-160. The LH-RH receptors showed a low-binding affinity (K(d) = 54 nM) and high capacity (B(max) = 12.0 pmol/mg). Treatment with the [D-Trp6]LH-RH decreased the binding affinity (K(d) = 0.52 μM). Specific somatostatin receptors, with K(d) = 1.3 nM and B(max) = 543 pmol/mg, were also found. Treatment with [D-Trp6]LH-RH lowered B(max) to 44 fmol/mg, and administration of RC-160 reduced K(d) to 30 nM. After the combined treatment with the two analogs, K(d) and B(max) were decreased. Specific PRL receptors (K(d) = 0.72 nM; B(max) = 161 fmol/mg) were also detected. Treatment with either analog reduced B(max) by 50{\%}, but a much greater reduction of PRL binding capacity was revealed after in vitro dissociation of the bound endogenous PRL by MgCl2. The dramatic fall in the total number of PRL receptors after combination treatment with both analogs could be partially responsible for the decrease in the weight and volume of prostate tumors. The findings support the concept that analogs of LH-RH and somatostatin can inhibit tumors directly through their own respective receptors. One of several mechanisms of the antineoplastic activity of these analogs could be the elimination of tumor growth-promoting effect of PRL by the reduction of the total number of PRL receptors.",
author = "T. Kadar and Redding, {T. W.} and M. Ben-David and Schally, {Andrew V}",
year = "1988",
month = "1",
day = "1",
language = "English",
volume = "85",
pages = "890--894",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "3",

}

TY - JOUR

T1 - Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin

AU - Kadar, T.

AU - Redding, T. W.

AU - Ben-David, M.

AU - Schally, Andrew V

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Membrane receptors for luteinizing hormone-releasing hormone (LH-RH), somatostatin, and prolactin (PRL) were investigated in the Dunning R-3327H rat prostate adenocarcinoma specimens after in vivo treatment with microcapsules of the agonist [D-Trp6]LH-RH and the somatostatin analog RC-160. The LH-RH receptors showed a low-binding affinity (K(d) = 54 nM) and high capacity (B(max) = 12.0 pmol/mg). Treatment with the [D-Trp6]LH-RH decreased the binding affinity (K(d) = 0.52 μM). Specific somatostatin receptors, with K(d) = 1.3 nM and B(max) = 543 pmol/mg, were also found. Treatment with [D-Trp6]LH-RH lowered B(max) to 44 fmol/mg, and administration of RC-160 reduced K(d) to 30 nM. After the combined treatment with the two analogs, K(d) and B(max) were decreased. Specific PRL receptors (K(d) = 0.72 nM; B(max) = 161 fmol/mg) were also detected. Treatment with either analog reduced B(max) by 50%, but a much greater reduction of PRL binding capacity was revealed after in vitro dissociation of the bound endogenous PRL by MgCl2. The dramatic fall in the total number of PRL receptors after combination treatment with both analogs could be partially responsible for the decrease in the weight and volume of prostate tumors. The findings support the concept that analogs of LH-RH and somatostatin can inhibit tumors directly through their own respective receptors. One of several mechanisms of the antineoplastic activity of these analogs could be the elimination of tumor growth-promoting effect of PRL by the reduction of the total number of PRL receptors.

AB - Membrane receptors for luteinizing hormone-releasing hormone (LH-RH), somatostatin, and prolactin (PRL) were investigated in the Dunning R-3327H rat prostate adenocarcinoma specimens after in vivo treatment with microcapsules of the agonist [D-Trp6]LH-RH and the somatostatin analog RC-160. The LH-RH receptors showed a low-binding affinity (K(d) = 54 nM) and high capacity (B(max) = 12.0 pmol/mg). Treatment with the [D-Trp6]LH-RH decreased the binding affinity (K(d) = 0.52 μM). Specific somatostatin receptors, with K(d) = 1.3 nM and B(max) = 543 pmol/mg, were also found. Treatment with [D-Trp6]LH-RH lowered B(max) to 44 fmol/mg, and administration of RC-160 reduced K(d) to 30 nM. After the combined treatment with the two analogs, K(d) and B(max) were decreased. Specific PRL receptors (K(d) = 0.72 nM; B(max) = 161 fmol/mg) were also detected. Treatment with either analog reduced B(max) by 50%, but a much greater reduction of PRL binding capacity was revealed after in vitro dissociation of the bound endogenous PRL by MgCl2. The dramatic fall in the total number of PRL receptors after combination treatment with both analogs could be partially responsible for the decrease in the weight and volume of prostate tumors. The findings support the concept that analogs of LH-RH and somatostatin can inhibit tumors directly through their own respective receptors. One of several mechanisms of the antineoplastic activity of these analogs could be the elimination of tumor growth-promoting effect of PRL by the reduction of the total number of PRL receptors.

UR - http://www.scopus.com/inward/record.url?scp=1842335354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842335354&partnerID=8YFLogxK

M3 - Article

C2 - 2893378

AN - SCOPUS:1842335354

VL - 85

SP - 890

EP - 894

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 3

ER -